病毒载体相关共同研究及授权契约:2016年～2025年

本报告全面解读了全球领先生物製药公司签署的病毒载体协议，并提供了前所未有的存取权限。

本报告详细解读并分析了公司签署病毒载体协议的方式和原因。这些协议通常涉及多个方面，通常始于合作研发，最终发展到成果商业化。

合作协议涵盖各种类型，包括合作研发和授权协议。

本报告提供了自2016年以来已宣布的413项病毒载体相关协议的完整列表，并儘可能包含财务条款。此外，报告还提供了每项协议的在线记录链接，方便您参考实际公开的协议。此外，记录中还包含公司和/或合作伙伴向美国证券交易委员会 (SEC) 提交的合约文件（如有）。

主要优势：

• 了解自2016年以来的交易趋势
• 查看病毒载体的合作与授权协议
• 基准分析：确定交易的市场价值
• 详细的财务条款：预付款、里程碑付款、特许权使用费
• 按公司名称（A-Z）、交易类型和治疗领域排序的交易目录
• 按价值排序的热门交易
• 最活跃的交易撮合者
• 确定每笔交易的资产和条款
• 存取合约文件：深入了解合约结构
• 尽职调查：评估拟议合约条款是否适合您的合作伙伴
• 节省数百小时的研究时间

合约分析可让您对以下内容进行尽职调查：

• 具体授予或选择哪些权利？
• 合约实际上赋予了合作伙伴什么？
• 授予了哪些独家权利？
• 合约的付款结构是怎样的？
• 如何审计销售和付款？
• 合约期间（生效期间）是多久？
• 合约的主要条款是如何界定的？
• 如何处理知识产权 (IPR)，由谁持有？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和成果揭露？
• 如何解决争议？
• 合约在什么情况下可以终止？
• 如果公司所有权发生变化，合约会怎样？
• 如何约定再授权和分包条款？
• 公司通常会包含哪些 "范本条款" ？
• 根据合约当事人和合约类型，有哪些 "范本条款" ？
• 公司要求哪个司法管辖区作为合约法下的准据法？

目录

摘要整理

第1章 简介

第2章 病毒载体契约趋势

• 各年度的病毒载体契约数量
• 最活跃的契约缔结企业
• 病毒载体契约:各类型契约
• 病毒载体契约:各治疗领域
• 病毒载体契约:各业界
• 病毒载体契约的交易条件

第3章 主要病毒载体契约

• 主要病毒载体契约:契约各金额

第4章 最活跃的病毒载体契约缔结企业

• 最活跃的病毒载体契约缔结企业
• 最活跃的病毒载体契约缔结企业简介

第5章 病毒载体契约的交易名录

• 病毒载体契约的交易名录

第6章 病毒载体契约:各技术类型

• 契约名录
• 契约名录- 各企业 (A-Z)
• 契约名录- 各类型契约
• 契约名录- 各治疗领域
• 契约类型定义
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering最近的报告标题

Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of viral vector deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter viral vector deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 413 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of viral vector dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral vector dealmaking since 2016.

Chapter 3 provides an overview of the leading viral vector deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of viral vector deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in viral vector deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse viral vector collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Viral Vector Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of viral vector trends and structure of deals entered into by leading biopharma companies worldwide.

Viral Vector Collaboration and Licensing Deals includes:

• Trends in viral vector dealmaking in the biopharma industry
• Directory of viral vector deal records covering pharmaceutical and biotechnology
• The leading viral vector deals by value
• Most active viral vector licensing dealmakers
• Viral Vector Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral vector dealmaking

• 2.1. Introduction
• 2.2. Viral vector deals over the years
• 2.3. Most active viral vector dealmakers
• 2.4. Viral vector deals by deal type
• 2.5. Viral vector deals by therapy area
• 2.6. Viral vector deals by industry sector
• 2.7. Deal terms for viral vector deals
  • 2.7.1 Viral vector deals headline values
  • 2.7.2 Viral vector deal upfront payments
  • 2.7.3 Viral vector deal milestone payments
  • 2.7.4 Viral vector royalty rates

Chapter 3 - Leading viral vector deals

• 3.1. Introduction
• 3.2. Top viral vector deals by value

Chapter 4 - Most active viral vector dealmakers

• 4.1. Introduction
• 4.2. Most active viral vector dealmakers
• 4.3. Most active viral vector deals company profiles

Chapter 5 - Viral vector contracts dealmaking directory

• 5.1. Introduction
• 5.2. Viral vector contracts dealmaking directory

Chapter 6 - Viral vector dealmaking by technology type

• Deal directory
• Deal directory - Viral vector deals by company A-Z
• Deal directory - Viral vector deals by deal type
• Deal directory - Viral vector deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Viral vector deals since 2016
• Figure 2: Active viral vector dealmaking activity - 2016 - 2025
• Figure 3: Viral vector deals by deal type since 2016
• Figure 4: Viral vector deals by therapy area since 2016
• Figure 5: Viral vector deals by industry sector since 2016
• Figure 6: Viral vector deals with a headline value
• Figure 7: Viral vector deals with an upfront value
• Figure 8: Viral vector deals with a milestone value
• Figure 9: Viral vector deals with a royalty rate value
• Figure 10: Top viral vector deals by value since 2016
• Figure 11: Most active viral vector dealmakers 2016 - 2025
• Figure 12: Viral vector deals by technology type since 2016